A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Phase 2
Completed
NCT05775289
| Condition | Non-small Cell Lung Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Hoffmann-La Roche |
|---|
| Status | Completed |
|---|
| Enrollment | 182 participants |
|---|
| Interventions | Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin |
|---|
| Start date | Mar 15, 2023 |
|---|
| Completion date | Jun 20, 2024 |
|---|
| Results posted | Nov 19, 2025 |
|---|
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.
Progression-Free Survival (PFS)
Randomization to date of first documented disease progression or death (up to approximately 15 months) · Months
| Pembro + Chemotherapy | 7.13 Months |
|---|
| Tobe + Chemotherapy | 7.62 Months |
|---|
| p-value | 0.9705 |
|---|
| Hazard Ratio (HR) | 0.99 (95% CI 0.63–1.56) |
|---|
Objective Response Rate (ORR)
Up to approximately 15 months · Percent of participants
| Pembro + Chemotherapy | 46.2 Percent of participants |
|---|
| Tobe + Chemotherapy | 41.1 Percent of participants |
|---|
| p-value | 0.4056 |
|---|
| Odds Ratio (OR) | 0.77 (95% CI 0.42–1.43) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.